{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Gilead Sciences, Inc."},"Symbol":{"label":"Symbol","value":"GILD"},"Address":{"label":"Address","value":"333 LAKESIDE DRIVE, FOSTER CITY, California, 94404, United States"},"Phone":{"label":"Phone","value":"+1 650 574-3000"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and noncell therapy in oncology."},"CompanyUrl":{"label":"Company Url","value":"https://www.gilead.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Daniel P. O'Day","title":"Chairman & Chief Executive Officer"},{"name":"Flavius Martin","title":"Executive Vice President-Research"},{"name":"Merdad V. Parsey","title":"Chief Medical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}